Bringing immunotherapy to clinical practice in dMMR/MSI-high colon cancer

IF 44.5 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2025-10-02 DOI:10.1016/j.ccell.2025.08.010

Giovanni Randon, Isacco Montroni, Filippo Pietrantonio

引用次数: 0

Abstract

Upfront resection is the standard treatment for localized dMMR/MSI-high colon cancer. In this issue of Cancer Cell, Wang et al. showed that dual anti-CTLA-4/PD-1 IBI310/sintilimab for 6 weeks improved pathological complete response over sintilimab in patients with cT4/N+ tumors. This combination represents a referral regimen for neoadjuvant or organ-preserving strategies.

查看原文本刊更多论文

将免疫疗法引入dMMR/ msi高结肠癌的临床实践

前期切除是局部dMMR/ msi高结肠癌的标准治疗方法。在这一期的Cancer Cell中，Wang等人发现，cT4/N+肿瘤患者的双重抗ctla -4/PD-1 IBI310/ sintilmab治疗6周，比sintilmab改善了病理完全缓解。这种组合代表了新辅助或器官保存策略的转诊方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.